Trials / Completed
CompletedNCT00476385
Practicability and Acceptability of Stylomax® in Children
Usability and Acceptability of Stylomax® in Growth Hormone Deficient Children.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: to evaluate the practicability and acceptability of STYLOMAX®, a new injection device for MAXOMAT®, in children, for 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropine | subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-12-01
- First posted
- 2007-05-22
- Last updated
- 2009-02-12
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00476385. Inclusion in this directory is not an endorsement.